

Oct 1, 2018

To Whom It May Concern,

Company Name: Taisho Pharmaceutical Holdings Co., Ltd.  
Head Office: 3-24-1, Takada, Toshima-ku, Tokyo  
Representative: Akira Uehara, Chief Executive Officer  
(Representative)  
(First Section of TSE: Code 4581)  
Contact: Hideki Iuchi, General Manager of  
Corporate Communications  
(Tel: +81-3-3985-1115)

### Notice of Change of Trade Name of Subsidiary

Taisho Pharmaceutical Holdings Co., Ltd. (Headquartered in Toshima-ku, Tokyo; Chief Executive Officer: Akira Uehara; hereinafter referred to as the “Company”) hereby announces that its consolidated subsidiary, Taisho Toyama Pharmaceutical Co., Ltd. (Headquartered in Toshima-ku, Tokyo; President: Kenichi Fujita; hereinafter referred to as “Taisho Toyama”), resolved at a meeting of its board of directors held on September 29 to change the trade name on April 1, 2019. The change was approved at its extraordinary general meeting of shareholders held on September 29. Details are as follows.

#### 1. Summary of the subsidiary

(1) Name	Taisho Toyama Pharmaceutical Co., Ltd.
(2) Location	25-1, Takada 3-chome, Toshima-ku, Tokyo
(3) Title and name of representative	President (Representative): Kenichi Fujita
(4) Business fields	Sales of ethical pharmaceuticals
(5) Capital	¥2,000 million
(6) Date of establishment	October 8, 2002

#### 2. Reasons for change

As Taisho Toyama became a wholly owned subsidiary of the Company, the trade name will be changed to increase and strengthen connections with the Group.

#### 3. New trade name

Taisho Pharma Co., Ltd.

#### 4. Scheduled date of change

April 1, 2019